Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Disease characteristics, age, and geography are among the main factors that shape first-line treatment patterns in patients ...

Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Please provide your email address to receive an email when new articles are posted on . Patients who achieved undetectable measurable residual disease had a 72% reduced risk for disease progression or ...

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? In the article that accompanies this editorial, ...